<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Evidence &amp; Research Archives - MoleMax Systems</title>
	<atom:link href="https://molemaxsystems.com/category/evidence-research/feed/" rel="self" type="application/rss+xml" />
	<link>https://molemaxsystems.com/category/evidence-research/</link>
	<description>Provide the best skin imaging device</description>
	<lastBuildDate>Wed, 05 Aug 2026 08:51:26 +0000</lastBuildDate>
	<language>en-AU</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://molemaxsystems.com/wp-content/uploads/2020/10/favicon.png</url>
	<title>Evidence &amp; Research Archives - MoleMax Systems</title>
	<link>https://molemaxsystems.com/category/evidence-research/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Mole Mapping Technology: What It Is, How It Works, and Why Clinics Are Adopting It </title>
		<link>https://molemaxsystems.com/mole-mapping-technology-what-it-is-how-it-works-and-why-clinics-are-adopting-it/</link>
		
		<dc:creator><![CDATA[keshab]]></dc:creator>
		<pubDate>Wed, 08 Jul 2026 02:42:33 +0000</pubDate>
				<category><![CDATA[Evidence & Research]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=10127</guid>

					<description><![CDATA[<p>Discover how mole mapping technology combines total body photography, dermoscopy and change tracking to support earlier melanoma detection and monitoring.</p>
<p>The post <a href="https://molemaxsystems.com/mole-mapping-technology-what-it-is-how-it-works-and-why-clinics-are-adopting-it/">Mole Mapping Technology: What It Is, How It Works, and Why Clinics Are Adopting It </a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Skin cancer is one of the most common cancers globally and one of the most survivable when caught early. Mole mapping technology is changing how dermatologists detect and&nbsp;monitor&nbsp;suspicious skin changes before they become life-threatening. If you are a clinic owner evaluating this system, or a patient trying to understand what the procedure involves, this guide covers everything you need to make an informed decision.&nbsp;</p>



<h2 class="wp-block-heading">What Is Mole Mapping Technology?&nbsp;</h2>



<p class="wp-block-paragraph"><a href="https://molemaxsystems.com/what-is-mole-mapping-and-how-does-it-work/" target="_blank" rel="noreferrer noopener">Mole mapping technology</a>&nbsp;is a clinical imaging system that photographs, documents, and digitally stores every mole and skin lesion on a patient&#8217;s body. It uses high-resolution cameras combined with specialized software to create a full-body skin record that is compared across multiple visits over time. The goal is not to diagnose cancer in a single session, it is to detect subtle changes in moles that may indicate early melanoma before they become visible to the naked eye.&nbsp;</p>



<p class="wp-block-paragraph">The technology works by establishing a baseline at the first appointment. Every subsequent visit compares current images against that baseline, allowing the dermatologist to identify new moles, changes in size or shape, or shifts in color that might otherwise go unnoticed during a standard examination.&nbsp;</p>



<h3 class="wp-block-heading">How Is It Different from a Regular Skin Check?&nbsp;</h3>



<p class="wp-block-paragraph">A regular skin check is a visual examination conducted during a single appointment, typically with a handheld&nbsp;<a href="https://molemaxsystems.com/product-category/dermlite/dermatoscopes/" target="_blank" rel="noreferrer noopener">dermatoscope</a>. It captures what the clinician sees today — but nothing is stored, measured, or compared to a previous visit.&nbsp;</p>



<p class="wp-block-paragraph">Mole mapping creates a permanent, structured digital record. It does not replace the clinical examination; it adds a longitudinal dimension to it. The difference is between a photograph and a video, one captures a moment, the other captures change.&nbsp;</p>



<h3 class="wp-block-heading">What Does &#8220;Total Body Photography&#8221; Mean?&nbsp;</h3>



<figure class="wp-block-image size-large"><img fetchpriority="high" decoding="async" width="1024" height="683" src="https://molemaxsystems.com/wp-content/uploads/2026/05/PSKY5302-Edit-1024x683.jpg" alt="" class="wp-image-9839" srcset="https://molemaxsystems.com/wp-content/uploads/2026/05/PSKY5302-Edit-1024x683.jpg 1024w, https://molemaxsystems.com/wp-content/uploads/2026/05/PSKY5302-Edit-300x200.jpg 300w, https://molemaxsystems.com/wp-content/uploads/2026/05/PSKY5302-Edit-768x512.jpg 768w, https://molemaxsystems.com/wp-content/uploads/2026/05/PSKY5302-Edit-1536x1024.jpg 1536w, https://molemaxsystems.com/wp-content/uploads/2026/05/PSKY5302-Edit-2048x1365.jpg 2048w, https://molemaxsystems.com/wp-content/uploads/2026/05/PSKY5302-Edit-900x600.jpg 900w, https://molemaxsystems.com/wp-content/uploads/2026/05/PSKY5302-Edit-600x400.jpg 600w, https://molemaxsystems.com/wp-content/uploads/2026/05/PSKY5302-Edit-400x267.jpg 400w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>



<p class="wp-block-paragraph">Total body photography is the clinical term used interchangeably with full body mole mapping. It refers to the systematic, standardized photography of the entire skin surface — from scalp to feet,&nbsp;using high-resolution imaging equipment.&nbsp;</p>



<p class="wp-block-paragraph">It is the imaging step within the broader mole mapping process. The full process also includes individual lesion dermoscopy, AI-assisted analysis, and follow-up comparison. Total body photography is what produces the baseline body map that everything else is built on.&nbsp;</p>



<h2 class="wp-block-heading">How Does Mole Mapping Work? Step-by-Step&nbsp;</h2>



<p class="wp-block-paragraph">Mole mapping follows a structured five-step process. Here is exactly what happens from the moment a patient walks in to the moment they leave with a follow-up plan.&nbsp;</p>



<h3 class="wp-block-heading">Step 1:&nbsp;Consultation and Skin History&nbsp;</h3>



<p class="wp-block-paragraph">The appointment begins with a clinical interview. The dermatologist or nurse records the patient&#8217;s total mole count, any history of atypical moles, personal or family history of melanoma, and cumulative sun exposure. This information builds a risk profile that determines how frequently the patient should be monitored and whether insurance coverage may apply.&nbsp;</p>



<p class="wp-block-paragraph">This step also sets expectations. Patients are told what the procedure involves, how images will be stored, and what outcomes to expect from the session.&nbsp;</p>



<h3 class="wp-block-heading">Step 2:&nbsp;Full-Body Image Capture&nbsp;</h3>



<p class="wp-block-paragraph">The patient is guided through a series of standardized poses while a high-resolution camera system photographs every surface of the body. This step typically takes 15 to 30 minutes. Standardized poses are critical — they ensure that images from one visit can be accurately aligned and compared against images from the next.&nbsp;</p>



<p class="wp-block-paragraph">Body regions covered include the face, scalp, neck, chest, back, abdomen, arms, hands, legs, and feet. No area is skipped, because melanoma can develop anywhere on the skin, including regions patients rarely examine themselves.&nbsp;</p>



<h3 class="wp-block-heading">Step 3:&nbsp;Dermoscopic Imaging of Individual Lesions&nbsp;</h3>



<p class="wp-block-paragraph">After full-body photography, the dermatologist uses a dermatoscope — a handheld device that magnifies and illuminates the skin&#8217;s surface — to capture close-up images of individual moles flagged as atypical or worth monitoring closely.&nbsp;</p>



<p class="wp-block-paragraph">These dermoscopic images are linked to their precise location on the full-body map, creating a two-layer record: the macro view showing where a mole sits on the body, and the micro view showing its internal structure in detail. This combination is what makes mole mapping significantly more powerful than either technique used alone.&nbsp;</p>



<h3 class="wp-block-heading">Step 4:&nbsp;AI Analysis and Change Detection&nbsp;</h3>



<p class="wp-block-paragraph">At this stage, the system&#8217;s artificial intelligence compares current images against the stored baseline. The AI scans for changes in mole size, shape, color distribution, border irregularity, and texture across every documented lesion.&nbsp;</p>



<p class="wp-block-paragraph">Crucially, the AI does not diagnose. It flags, scores, and prioritizes. It presents the dermatologist with a ranked list of lesions that have changed most significantly since the last visit, allowing the clinician to focus their attention where it matters most rather than manually reviewing hundreds of stable moles. A 2020 study published in&nbsp;<em>Nature</em>&nbsp;found that a deep learning model outperformed 58 dermatologists in distinguishing malignant melanomas from benign lesions, achieving an AUC of 0.94 — underscoring the clinical value AI brings to this process.&nbsp;</p>



<h3 class="wp-block-heading">Step 5:&nbsp;Report and Follow-Up Scheduling&nbsp;</h3>



<p class="wp-block-paragraph">The session concludes with a structured report listing all flagged lesions, their body map location, dermoscopic images, and a change summary for returning patients. The dermatologist reviews the report and gives the patient one of three outcomes: discharge with an annual review, a follow-up appointment in six months, or an immediate biopsy referral for a concerning lesion.&nbsp;</p>



<p class="wp-block-paragraph">The images are stored and become the patient&#8217;s permanent skin record — the asset that grows more valuable with every visit.&nbsp;</p>



<h2 class="wp-block-heading">Who Should Get Mole Mapping?&nbsp;</h2>



<p class="wp-block-paragraph">Mole mapping is suitable for two broad groups: patients with an identified high-risk profile, and general adults who want to establish a proactive baseline before any problems develop.&nbsp;</p>



<h3 class="wp-block-heading">Which Patient Profiles Benefit Most?&nbsp;</h3>



<p class="wp-block-paragraph">Certain patients have a clinically elevated risk of developing melanoma and are the primary candidates for regular mole mapping:&nbsp;</p>



<ul class="wp-block-list">
<li><strong>Patients with more than 50 moles</strong>: The higher the mole count, the greater the statistical likelihood of one undergoing malignant change </li>
</ul>



<ul class="wp-block-list">
<li><strong>Patients with atypical or dysplastic nevi</strong> : Moles with irregular borders, mixed pigmentation, or asymmetric shape that require close longitudinal monitoring </li>
</ul>



<ul class="wp-block-list">
<li><strong>Patients with a personal history of melanoma: </strong>The risk of a second primary melanoma is significantly higher than average </li>
</ul>



<ul class="wp-block-list">
<li><strong>Patients with a first-degree relative diagnosed with melanoma: </strong>Genetic predisposition raises lifetime risk substantially </li>
</ul>



<p class="wp-block-paragraph">According to the Melanoma Institute Australia, regular mole mapping in high-risk populations can detect melanoma 80 to 160% earlier than in patients without systematic monitoring.&nbsp;</p>



<h3 class="wp-block-heading">Is It Only for High-Risk Patients?&nbsp;</h3>



<p class="wp-block-paragraph">No,&nbsp;but the clinical case for it is strongest in high-risk patients. Any adult can request mole mapping as a proactive baseline. The value of a single scan is limited; the real power comes from serial monitoring over two, five, or ten years.&nbsp;</p>



<p class="wp-block-paragraph">For clinics, this means mole mapping serves two distinct patient groups with different clinical rationales and different conversation approaches. High-risk patients need mole mapping. General adults who want it are making a proactive choice that deserves to be supported, not discouraged.&nbsp;</p>



<h2 class="wp-block-heading">Types of Mole Mapping Technology Used in Clinics&nbsp;</h2>



<p class="wp-block-paragraph">Not all mole mapping systems are the same. There are three distinct technology tiers in clinical use today and the differences between them have significant implications for diagnostic accuracy, workflow efficiency, and procurement cost. </p>



<ol start="1" class="wp-block-list">
<li>Standard Digital Dermoscopy Systems </li>
</ol>



<p class="wp-block-paragraph">These are handheld or table-mounted&nbsp;dermoscopes&nbsp;connected to&nbsp;a digital&nbsp;camera and image management software. The clinician selects which moles to photograph based on their own visual assessment during the examination.&nbsp;Images are stored and can be reviewed at follow-up appointments.&nbsp;</p>



<p class="wp-block-paragraph">This is the entry-level tier. It is suitable for smaller practices with a lower volume of high-risk patients. The core limitation is clinician-dependent&nbsp;selection&nbsp;— lesions the clinician does not flag during the examination will not be imaged, which introduces a potential for missed detection.&nbsp;</p>



<ol start="2" class="wp-block-list">
<li>Automated Total Body Photography Systems </li>
</ol>



<p class="wp-block-paragraph">These systems use multiple cameras in a standardized array, or a single camera guided through a structured protocol, to photograph the entire body surface systematically in one session. The patient does not need the clinician to decide which moles to capture the&nbsp;system captures everything.&nbsp;</p>



<p class="wp-block-paragraph">Images are automatically organized into a full-body map and stored for comparison. This tier removes selection bias and ensures comprehensive coverage. It is the standard of care in dedicated melanoma screening clinics and is increasingly being adopted in mid-to-large dermatology practices.&nbsp;</p>



<ol start="3" class="wp-block-list">
<li>AI-Integrated Mole Mapping Platforms </li>
</ol>



<p class="wp-block-paragraph">The most advanced tier adds a machine learning layer on top of automated imaging. The AI compares current images with stored baseline images, scores each lesion for degree of change, and surfaces the highest-priority cases for dermatologist review.&nbsp;</p>



<p class="wp-block-paragraph">This tier dramatically reduces the time a dermatologist spends reviewing stable moles — which in a high-volume practice can represent the majority of a follow-up appointment.&nbsp;For clinics managing hundreds of&nbsp;monitored&nbsp;patients, AI-integrated platforms convert mole mapping from a time-intensive process into a scalable clinical program.&nbsp;</p>



<ol start="4" class="wp-block-list">
<li>Cost and Insurance Coverage </li>
</ol>



<p class="wp-block-paragraph">The cost of mole mapping varies significantly depending on&nbsp;country, clinic type, and the technology tier being used. Insurance coverage exists in some cases but is not guaranteed,&nbsp;and understanding this upfront prevents frustration for both clinics and patients.&nbsp;</p>



<h3 class="wp-block-heading">How Much Does Mole Mapping Cost?&nbsp;</h3>



<p class="wp-block-paragraph">In the United States, out-of-pocket costs for a full mole mapping session typically range from $150 to $400. This usually includes full-body image capture,&nbsp;<a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/" target="_blank" rel="noreferrer noopener">dermoscopic imaging</a>&nbsp;of individual lesions, digital storage, and physician analysis. One example pricing structure charges $250 for patients without insurance coverage, covering all four components in a single appointment fee.&nbsp;</p>



<p class="wp-block-paragraph">The initial baseline appointment is always more expensive than follow-up visits, because it involves establishing the full-body map from scratch. Follow-up appointments focus on comparison and flagging changes, which takes less clinical time and usually costs less.&nbsp;</p>



<p class="wp-block-paragraph">In Australia and the United Kingdom, costs depend on whether the clinic is public, private, or operating under a national skin cancer screening program. Prices and coverage rules differ significantly across these markets.&nbsp;</p>



<h3 class="wp-block-heading">Is It Covered by Insurance?&nbsp;</h3>



<p class="wp-block-paragraph">Coverage is inconsistent and should never be assumed. Insurance plans may cover mole mapping for patients with multiple dysplastic nevi, a personal history of melanoma, or a documented family history of melanoma but many insurers do not cover it at all.&nbsp;</p>



<p class="wp-block-paragraph">Where coverage exists, prior authorization is often required before the appointment. Patients should contact their insurer directly and ask their dermatologist to provide written documentation of medical necessity before booking. It is also important to note that mole mapping is not classified as preventive care under most insurance plans, which means it does not fall under free preventive benefit provisions even for patients with comprehensive coverage.&nbsp;</p>



<h2 class="wp-block-heading">Why Are Clinics Investing in This Technology?&nbsp;</h2>



<p class="wp-block-paragraph">Clinics adopting mole mapping technology are responding to three converging drivers: demonstrable clinical benefits, rising patient demand for proactive skin care, and a rapidly growing global market that rewards early adoption.&nbsp;</p>



<h3 class="wp-block-heading">Clinical Benefits for the Practice&nbsp;</h3>



<p class="wp-block-paragraph">The most immediate clinical benefit is a reduction in unnecessary biopsies. When a dermatologist has two years of longitudinal imaging showing a mole has been completely stable, the case for biopsy weakens significantly. Research has shown that baseline mole mapping combined with AI analysis reduces unnecessary biopsies while simultaneously detecting melanoma at an earlier, more treatable stage.&nbsp;</p>



<p class="wp-block-paragraph">For the practice, fewer unnecessary biopsies means lower pathology costs, less patient anxiety, and more efficient appointment time. A dermatologist who can review an AI-prioritized list of changed lesions rather than manually examining every documented mole in a patient&#8217;s record spends their clinical time where it genuinely matters.&nbsp;</p>



<h3 class="wp-block-heading">Market Size and Growth&nbsp;</h3>



<p class="wp-block-paragraph">The global AI dermatology mole mapping market reached USD 1.47 billion in 2024 and is projected to grow at a compound annual growth rate of 19.2% through 2033, reaching USD 6.25 billion. This growth is driven by rising global skin cancer incidence, rapid advances in AI imaging accuracy, and increasing clinical demand for systematic early detection protocols.&nbsp;</p>



<p class="wp-block-paragraph">Clinics investing in mole mapping technology now are entering a market that is still in its institutional adoption phase — not saturation. The practices that build mole mapping programs today will hold a significant patient acquisition and retention advantage as demand accelerates over the next decade.&nbsp;</p>



<p class="wp-block-paragraph"><strong><em>See how&nbsp;MoleMax&nbsp;fits into your clinic&#8217;s diagnostic workflow:&nbsp;</em></strong><a href="https://molemaxsystems.com/online-demo-request" target="_blank" rel="noreferrer noopener"><strong><em>book a 15-minute product demo today</em></strong></a><strong><em>.</em></strong>&nbsp;</p>



<h2 class="wp-block-heading">Frequently Asked Questions&nbsp;</h2>



<h3 class="wp-block-heading">How Often Should Mole Mapping Be Repeated?&nbsp;</h3>



<p class="wp-block-paragraph">Most dermatologists recommend annual mole mapping for high-risk patients. Patients with rapidly changing lesions or a prior melanoma diagnosis may be scheduled every six months. The interval is always determined by the individual&#8217;s risk profile — there is no universal fixed schedule.&nbsp;</p>



<h3 class="wp-block-heading">Can Mole Mapping Detect Melanoma?&nbsp;</h3>



<p class="wp-block-paragraph">Mole mapping does not diagnose melanoma. Only a biopsy followed by histopathological laboratory analysis can confirm a diagnosis. Mole mapping detects changes in lesions that may warrant a biopsy. Its clinical value lies in identifying suspicious changes at the earliest possible stage, when melanoma is most treatable and outcomes are best.&nbsp;</p>



<h3 class="wp-block-heading">What Is the Difference Between Mole Mapping and Dermoscopy?&nbsp;</h3>



<p class="wp-block-paragraph">Dermoscopy is a technique using a handheld magnification device to examine individual moles in close detail during a single appointment. Mole mapping is a broader clinical system that uses&nbsp;<a href="https://molemaxsystems.com/dermoscopy-vs-digital-dermoscopy-whats-the-difference/" target="_blank" rel="noreferrer noopener">dermoscopy</a>&nbsp;as one component alongside full-body photography, digital storage, AI analysis, and longitudinal comparison across multiple visits. Dermoscopy examines one mole today; mole mapping tracks all moles over years.&nbsp;</p>



<h3 class="wp-block-heading">Is Mole Mapping Covered by Insurance?&nbsp;</h3>



<p class="wp-block-paragraph">Coverage depends entirely on the patient&#8217;s risk profile and their specific insurance plan. Patients with a documented history of atypical moles, personal melanoma diagnosis, or first-degree relative with melanoma are more likely to qualify for partial or full coverage. Prior authorization is often required. Mole mapping is not classified as preventive care under most plans, so standard preventive benefit provisions do not apply. Always verify coverage with your insurer before the appointment.&nbsp;</p>



<p class="wp-block-paragraph"></p>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/mole-mapping-technology-what-it-is-how-it-works-and-why-clinics-are-adopting-it/">Mole Mapping Technology: What It Is, How It Works, and Why Clinics Are Adopting It </a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Skin Cancer Risk Profile of Asymptomatic Patients Seeking Periodic Skin Examinations for Skin Cancer Concerns</title>
		<link>https://molemaxsystems.com/skin-cancer-risk-profile-of-asymptomatic-patients-seeking-periodic-skin-examinations-for-skin-cancer-concerns/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 26 May 2026 02:46:59 +0000</pubDate>
				<category><![CDATA[Evidence & Research]]></category>
		<category><![CDATA[dematology research]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9900</guid>

					<description><![CDATA[<p>Skin cancer risk factors in asymptomatic screening patients</p>
<p>The post <a href="https://molemaxsystems.com/skin-cancer-risk-profile-of-asymptomatic-patients-seeking-periodic-skin-examinations-for-skin-cancer-concerns/">Skin Cancer Risk Profile of Asymptomatic Patients Seeking Periodic Skin Examinations for Skin Cancer Concerns</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a889d7ad941f"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row top-level"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p><span class="wi-fullname brand-fg">Yin Li, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Robert A. Swerlick, MD</span></p>
<div class="h3 cb section-type-abstract decorated-hed ">
<h3 class="heading-text thm-col sb-sc"><strong>Abstract</strong></h3>
</div>
<div id="AbstractSection">
<p><strong>Importance</strong>  Periodic comprehensive skin examinations of asymptomatic individuals are widely accepted by dermatologists and the public, resulting in deployment of skin cancer (SC) surveillance practices that may include patients at low risk for SC.</p>
<p><strong>Objective</strong>  To define the demographics, SC risk factors, and near-term outcomes of asymptomatic individuals seeking comprehensive skin examinations.</p>
<p><strong>Design, Setting, and Participants</strong>  This cross-sectional study is a secondary analysis of data collected through a routine, previsit survey completed by patients who visited the Emory Healthcare Dermatology Clinic between March 2021 and October 2022. This study involved new patients who had no specific skin complaints and requested a general skin examination because they had general concerns about SC. Data were analyzed between from July to December 2025.</p>
<p><strong>Main Outcomes and Measures</strong>  The main objective was to identify patients at higher risk for SC development by evaluating characteristics including demographics and SC risk factors including skin phototype, eye and hair color, and family and personal history of SC. The number needed to examine to diagnose 1 SC was calculated for the entire cohort and for subgroups.</p>
<p><strong>Results</strong>  A total of 1074 new patients who noted no skin complaints but sought examinations for concerns about SC were identified (mean [SD] age, 50.3 [15.9] years; 643 [59.9%] female). Of these patients, 186 reported a personal history of SC, with the percentage reporting a history of SC increasing with age. Among those reporting SC history, 184 (99.5%) had skin phototypes I through III. Overall, 131 patients (12.2%) underwent 146 skin biopsies, and 38 SCs were diagnosed. Three patients younger than 50 years were diagnosed with SC, and 37 of 38 SCs were diagnosed in patients with skin types I through III. The number needed to be examined to diagnose 1 SC was 181 in patients 50 years or younger and 7 in patients 70 years or older. The number needed to examine for patients with and without a history of SC was 12 and 52, respectively.</p>
<p><strong>Conclusions and Relevance</strong>  This study found that populations of new patients without specific skin complaints seeking care for SC surveillance may contain substantial percentages of people at low risk for diagnosis of SC. Implementation of simple triage criteria for asymptomatic patients seeking SC surveillance based on age, skin phototype, and SC history could select for patients at substantially higher risk for SC diagnosis.</p>
<p>To read the full article please <a href="https://jamanetwork.com/journals/jamadermatology/fullarticle/2848896?guestAccessKey=e667353f-cfd2-411f-b6a8-9108619aa0e4&amp;utm_medium=email&amp;utm_source=postup_jn&amp;utm_campaign=article_alert-jamadermatology&amp;utm_content=olf-tfl_&amp;utm_term=052026" target="_blank" rel="noopener">click here</a>.</p>
</div>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/skin-cancer-risk-profile-of-asymptomatic-patients-seeking-periodic-skin-examinations-for-skin-cancer-concerns/">Skin Cancer Risk Profile of Asymptomatic Patients Seeking Periodic Skin Examinations for Skin Cancer Concerns</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Rethinking Melanocytic Tumors: A Critical Appraisal of the WHO Classification and the Myth of Nevus-to-Melanoma Progression</title>
		<link>https://molemaxsystems.com/rethinking-melanocytic-tumors-a-critical-appraisal-of-the-who-classification-and-the-myth-of-nevus-to-melanoma-progression/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 12 May 2026 00:26:00 +0000</pubDate>
				<category><![CDATA[Evidence & Research]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[dermoscopy]]></category>
		<category><![CDATA[melanoma]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9679</guid>

					<description><![CDATA[<p>A critical review of melanocytic tumor classification</p>
<p>The post <a href="https://molemaxsystems.com/rethinking-melanocytic-tumors-a-critical-appraisal-of-the-who-classification-and-the-myth-of-nevus-to-melanoma-progression/">Rethinking Melanocytic Tumors: A Critical Appraisal of the WHO Classification and the Myth of Nevus-to-Melanoma Progression</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a889d7adb663"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p>Giuseppe Argenziano, Giulia Briatico, Eugenia Veronica Di Brizzi, Camila Scharf, Gabriella Brancaccio, Elvira Moscarella, Maria Maddalena Nicoletti, Pasquale Verolino, Aimilios Lallas, Harald Kittler</p>
<p>&nbsp;</p>
<h3><strong>ABSTRACT</strong></h3>
<p><strong>Introduction</strong>: The recent WHO classification of melanocytic tumors introduces a refined molecular and histopathological framework suggesting distinct pathways and precursor lesions for all melanoma subtypes. While conceptually appealing, its clinical applicability is increasingly questioned.</p>
<p><strong>Objectives</strong>: This review critically examines the transformation theory from benign nevi to melanoma, highlighting inconsistencies between the proposed models and real-life practice.</p>
<p><strong>Methods</strong>: Through illustrative cases and key epidemiological evidence, we evaluated the validity of current models proposing intermediate lesions in melanoma development.</p>
<p><strong>Results</strong>: We argue that most melanomas arise de novo and that the so-called intermediate lesions, such as dysplastic nevi and atypical Spitz tumors, may mimic melanoma but are not true biological precursors.</p>
<p><strong>Conclusions</strong>: We propose a simplified, clinically oriented reclassification of melanocytic lesions based on morphologic ambiguity and actual behavior, aiming to guide therapeutic decisions and reduce di-agnostic overinterpretation.</p>
<p>To access the full article please <a href="https://dpcj.org/index.php/dpc/article/view/6994/3276" target="_blank" rel="noopener">click here</a>.</p>
<p>&nbsp;</p>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/rethinking-melanocytic-tumors-a-critical-appraisal-of-the-who-classification-and-the-myth-of-nevus-to-melanoma-progression/">Rethinking Melanocytic Tumors: A Critical Appraisal of the WHO Classification and the Myth of Nevus-to-Melanoma Progression</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Spontaneous Regression of Well-Differentiated Squamous Cell Skin Cancer Following Partial, Diagnostic Biopsy: Retrospective Cohort in Queensland</title>
		<link>https://molemaxsystems.com/spontaneous-regression-of-well-differentiated-squamous-cell-skin-cancer-following-partial-diagnostic-biopsy-retrospective-cohort-in-queensland/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 14 Apr 2026 00:44:00 +0000</pubDate>
				<category><![CDATA[Evidence & Research]]></category>
		<category><![CDATA[dermatology research]]></category>
		<category><![CDATA[Squamous Cell Carcinoma]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9575</guid>

					<description><![CDATA[<p>Spontaneous regression observed after biopsy of squamous carcinoma</p>
<p>The post <a href="https://molemaxsystems.com/spontaneous-regression-of-well-differentiated-squamous-cell-skin-cancer-following-partial-diagnostic-biopsy-retrospective-cohort-in-queensland/">Spontaneous Regression of Well-Differentiated Squamous Cell Skin Cancer Following Partial, Diagnostic Biopsy: Retrospective Cohort in Queensland</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a889d7add287"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p><span class="name western">David Wilkinson</span>, <span class="name western">Julia Sottovia</span>, <span class="name western">Sonje Hoogstad</span></p>
<h2 data-anchor-id="abstract1">Abstract</h2>
<section id="sec1">
<h3 class="pmc_sec_title"><strong>Introduction</strong></h3>
<p>Well-differentiated squamous cell skin cancer (WDSCC) is common in sun-exposed populations. Guidelines promote active treatment, with excision preferred. Isolated cases of spontaneous regression (SR) have been reported. Having observed multiple patients with apparent SR following partial, diagnostic biopsy, we did a retrospective cohort study to explore this further.</p>
</section>
<section id="sec2">
<h3 class="pmc_sec_title"><strong>Objectives</strong></h3>
<p>We sought to report frequency of SR of WDSCC following partial biopsy by a general practitioner (GP) in a primary care setting and referral to a public hospital general surgery service for excision, to report patient characteristics, and to estimate the time interval between biopsy and SR.</p>
</section>
<section id="sec3">
<h3 class="pmc_sec_title"><strong>Methods</strong></h3>
<p>Retrospective cohort study (22 months) of patients in Queensland, Australia, with a diagnosis of WD-SCC following a partial biopsy by a GP. SR was defined as no clinical or dermoscopy evidence of squamous cell carcinoma (SCC).</p>
</section>
<section id="sec4">
<h3 class="pmc_sec_title"><strong>Results</strong></h3>
<p>Among 153 consecutive patients with WDSCC referred for excision, 51 showed SR at consultation (33.3%, 95% CI: 25.6–41). There was no significant difference in age or sex of the SR and non-SR groups. In almost all patients with SR (N=49, 96.1%), lesions were located below the knee, compared with 90 (88.2%, <em>P</em>=0.042) without SR. Average interval between biopsy and surgical consultation was 13.6 weeks (range 2.7–24.7 weeks).</p>
</section>
<section id="sec5">
<h3 class="pmc_sec_title"><strong>Conclusions</strong></h3>
<p>WDSCC may spontaneously resolve following partial, diagnostic biopsy more often than previously reported. These preliminary observations may have implications for treatment options, especially among frail patients with comorbidities.</p>
<p>For information on the full article <a href="https://dpcj.org/index.php/dpc/article/view/5632/3252" target="_blank" rel="noopener">please click here</a>.</p>
</section>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/spontaneous-regression-of-well-differentiated-squamous-cell-skin-cancer-following-partial-diagnostic-biopsy-retrospective-cohort-in-queensland/">Spontaneous Regression of Well-Differentiated Squamous Cell Skin Cancer Following Partial, Diagnostic Biopsy: Retrospective Cohort in Queensland</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title> Why Is Workplace Safety Important? Definition &#038; Essential Safety Equipment?  </title>
		<link>https://molemaxsystems.com/why-is-workplace-safety-important-definition-essential-safety-equipment/</link>
		
		<dc:creator><![CDATA[keshab]]></dc:creator>
		<pubDate>Tue, 31 Mar 2026 05:47:53 +0000</pubDate>
				<category><![CDATA[Evidence & Research]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9204</guid>

					<description><![CDATA[<p>Why workplace safety matters for employees and businesses</p>
<p>The post <a href="https://molemaxsystems.com/why-is-workplace-safety-important-definition-essential-safety-equipment/"> Why Is Workplace Safety Important? Definition &#038; Essential Safety Equipment?  </a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Workplace safety is more than just a set of&nbsp;rules,&nbsp;it’s&nbsp;an important part of any successful business. A safe working environment protects employees from accidents, reduces health risks, and boosts overall productivity.&nbsp;</p>



<p class="wp-block-paragraph">Organisations&nbsp;that&nbsp;prioritise&nbsp;safety not only safeguard their staff but also build trust, enhance&nbsp;morale&nbsp;and&nbsp;minimise&nbsp;costly disruptions.&nbsp;</p>



<p class="wp-block-paragraph">In this blog, we will explore the importance of workplace safety, highlighting the essential safety equipment every workplace should have.&nbsp;&nbsp;</p>



<h2 class="wp-block-heading"><strong>5 Effective Ways to Improve Workplace Health And Safety </strong> </h2>



<p class="wp-block-paragraph">Workplace safety is the foundation of a healthy,&nbsp;productive&nbsp;and thriving work environment. When you&nbsp;prioritise&nbsp;safety, it helps to protect employees from injuries, reduces operational disruptions, and creates a culture of trust and responsibility.&nbsp;</p>



<p class="wp-block-paragraph">Here are 5 ways to improve workplace health and safety:&nbsp;</p>



<h3 class="wp-block-heading">1. Protects Employees from Injuries and Accidents&nbsp;</h3>



<p class="wp-block-paragraph">A safe workplace helps prevent everything from minor slips and falls to severe machinery‑related accidents. In Australia, about&nbsp;<a href="https://www.safeworkaustralia.gov.au/media-centre/news/key-work-health-and-safety-statistics-2024" target="_blank" rel="noreferrer noopener">3.5 % of workers experienced a work-related injury or illness</a>&nbsp;in the past 12 months. When employers invest in safety protocols, regular&nbsp;training&nbsp;and proper protective gear, there is a high chance of reducing these risks.&nbsp;&nbsp;</p>



<h3 class="wp-block-heading">2. Boosts Productivity and Efficiency&nbsp;</h3>



<p class="wp-block-paragraph">Safety and productivity go hand in hand. Employees who feel safe at work are more focused,&nbsp;engaged&nbsp;and motivated. When you have safety equipment, there will be fewer chances of accidents, which means less downtime, smoother&nbsp;workflows&nbsp;and uninterrupted operations.&nbsp;</p>



<h3 class="wp-block-heading">3. Reduces Financial Losses&nbsp;</h3>



<p class="wp-block-paragraph">Workplace accidents can be costly in many ways. Beyond the physical harm to employees, incidents result in medical bills, workers’ compensation claims, legal fees, and higher insurance premiums. Every organisation should invest in high-quality safety tools, such as head protection and clear safety signage, along with proper training and preventive measures. </p>



<h3 class="wp-block-heading">4. Ensures Compliance with Legal Standards&nbsp;</h3>



<p class="wp-block-paragraph">Governments and regulatory bodies in Australia require businesses to meet strict work health and safety (WHS) obligations under the model WHS laws. Failure to comply can lead to hefty fines, legal complications, and damage to a company’s reputation. When you follow safety regulations, businesses not only safeguard their employees but also&nbsp;demonstrate&nbsp;professionalism and a strong commitment to ethical practices.&nbsp;&nbsp;</p>



<h3 class="wp-block-heading">5. Builds a Positive Work Culture&nbsp;</h3>



<p class="wp-block-paragraph">When staff feel valued and secure, they are more engaged, motivated, and committed to their work. It’s important to prioritise safety, encourage teamwork, accountability, and shared responsibility, and create a collaborative environment. Over time, this positive work culture not only boosts employee morale but also strengthens overall business performance. </p>



<h2 class="wp-block-heading">Essential Workplace Safety Equipment You Must Have </h2>



<p class="wp-block-paragraph">A safe work environment starts with having the right safety equipment. Proper safety gear not only protects employees from accidents and injuries but also ensures compliance with legal standards and boosts overall productivity. Whether in an office, factory, or construction site, equipping your workplace with essential safety tools is a critical step toward reducing risks and fostering a culture of care.&nbsp;</p>



<p class="wp-block-paragraph">Here are the must-have workplace safety equipment items: </p>



<h3 class="wp-block-heading"><strong>1. Personal Protective Equipment (PPE): </strong></h3>



<p class="wp-block-paragraph">Personal Protective Equipment (PPE) includes helmets, gloves, safety goggles, high-visibility clothing and protective footwear. These items shield employees from hazards such as falling objects, chemical exposure and slips, helping prevent injuries on the job. </p>



<h3 class="wp-block-heading"><strong>2. Fire Safety Equipment:</strong> </h3>



<p class="wp-block-paragraph">Fire extinguishers, smoke alarms, fire blankets and emergency exit signage are crucial for preventing and managing fire emergencies. Regularly maintaining fire safety equipment ensures quick response and reduces potential damage. </p>



<h3 class="wp-block-heading"><strong>3. First Aid Kits:</strong> </h3>



<p class="wp-block-paragraph">Every workplace should have easily accessible first aid kits stocked with bandages, antiseptics and other essential medical supplies. Quick access to first aid can prevent minor injuries from becoming severe. </p>



<h3 class="wp-block-heading"><strong>4. Safety Signage and Warnings: </strong></h3>



<p class="wp-block-paragraph">Clear signs indicating hazards, emergency exits and safety procedures are essential. Visual reminders help employees stay aware of risks and follow safety protocols consistently. </p>



<h3 class="wp-block-heading"><strong>5. Ergonomic Equipment: </strong></h3>



<p class="wp-block-paragraph">Chairs, workstations and tools designed ergonomically reduce the risk of musculoskeletal injuries. Investing in ergonomic equipment promotes employee comfort and long-term health. </p>



<h3 class="wp-block-heading"><strong>6. Emergency and Evacuation Tools:</strong></h3>



<p class="wp-block-paragraph"><strong> </strong>Items such as emergency lighting, evacuation maps and alarm systems ensure that employees can safely exit the workplace during emergencies. Proper training on these tools is equally important. </p>



<h3 class="wp-block-heading"><strong>7. Protective Barriers and Guards:</strong> </h3>



<p class="wp-block-paragraph">In high-risk areas, installing safety barriers, machine guards and handrails helps prevent accidents and protects employees from moving machinery or hazardous zones. </p>



<h2 class="wp-block-heading"><strong>Final Takeaways on Workplace Safety</strong> </h2>



<p class="wp-block-paragraph">Workplace safety tools are essential for keeping everyone protected. By implementing proper safety measures in offices, ongoing construction&nbsp;sites&nbsp;and other work environments, the risk of accidents is reduced. Fewer accidents mean lower compensation claims and uninterrupted productivity.&nbsp;</p>



<p class="wp-block-paragraph">If you’re looking for essential workplace safety tools, the <a href="https://molemaxsystems.com/" target="_blank" rel="noreferrer noopener">MoleMax system</a> is a trusted choice. As a leading medical equipment supplier in Australia, we offer a wide range of products to help you maintain a safe and compliant workplace. Our <a href="https://macquariemed.com.au/first-aid-and-safety/workplace-safety" target="_blank" rel="noreferrer noopener">workplace safety tools</a> are designed to protect employees and visitors alike, enabling businesses to create environments where safety is always the top priority. </p>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/why-is-workplace-safety-important-definition-essential-safety-equipment/"> Why Is Workplace Safety Important? Definition &#038; Essential Safety Equipment?  </a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dermoscopic Features of Follicular Dermatoses: A Cross-Sectional Study</title>
		<link>https://molemaxsystems.com/dermoscopic-features-of-follicular-dermatoses-a-cross-sectional-study/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 31 Mar 2026 00:22:27 +0000</pubDate>
				<category><![CDATA[Evidence & Research]]></category>
		<category><![CDATA[dematology research]]></category>
		<category><![CDATA[Dermatoscope benefits]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9475</guid>

					<description><![CDATA[<p>Exploring dermoscopic patterns in follicular skin disorders</p>
<p>The post <a href="https://molemaxsystems.com/dermoscopic-features-of-follicular-dermatoses-a-cross-sectional-study/">Dermoscopic Features of Follicular Dermatoses: A Cross-Sectional Study</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a889d7ae16ae"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p>Rinni R Patel, Hita H Mehta, Manal D Dave</p>
<h3 class="_label"><strong>Abstract</strong></h3>
<p><strong>Introduction: </strong>Follicular dermatoses are conditions characterized by localization around hair follicles, often presenting as small papular lesions. These dermatoses can be challenging to diagnose with the naked eye, making dermoscopy an important adjunctive diagnostic tool. However, the literature on the dermoscopic features of follicular dermatoses remains limited.</p>
<p><strong>Objectives: </strong>To evaluate dermoscopic findings in follicular dermatoses.</p>
<p><strong>Methods: </strong>This cross-sectional study was conducted from November 2022 to January 2024 at the dermatology department of a tertiary hospital. Patients were categorized into inflammatory and keratinization follicular dermatosis. A fully developed lesion was dermoscopically examined using a DermLite DL-5 dermoscope. The data were statistically analyzed.</p>
<p><strong>Results: </strong>We studied 147 patients. Most follicular dermatoses on dermoscopy showed classical findings such as keratotic plugs, perifollicular white halo, or brown halo. However, they also exhibited characteristic features unique to each dermatoses. Keratosis pilaris exhibited coiled hair (77.41%). Reactive perforating collagenosis presented a central yellowish plug (100%), whitish rim (100%), and peripheral erythematous halo (87.5%). Follicular LP showed reduced follicular ostia (45.45%) and blue-gray globules (40.90%), with newer findings like radial white stria and rosette. Follicular psoriasis displayed regular red dots (100%), while follicular eczema showed red globules (50%) and irregular red dots (16.7%). Acne keloidalis nuchae exhibited radial white streaks (62.5%), perifollicular white globules (50%), V-shaped hair (50%), and radial linear vessels (18.75%). Darier disease showed central hyperpigmented and white keratotic plugs, comedo-like openings, and interfollicular exaggerated pseudo-pigment areas.</p>
<p><strong>Conclusion: </strong>Our study highlights that each follicular dermatosis presents specific dermoscopic patterns, supporting dermoscopy as a useful, noninvasive tool for differentiation that can complement histopathology.</p>
<p>To read the full article <a href="https://dpcj.org/index.php/dpc/article/view/5775/3741" target="_blank" rel="noopener">please click here</a>.</p>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/dermoscopic-features-of-follicular-dermatoses-a-cross-sectional-study/">Dermoscopic Features of Follicular Dermatoses: A Cross-Sectional Study</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Training Primary Care Practitioners In Dermoscopy Diagnostic Algorithms Enhances Diagnostic Accuracy and Triage of Suspected Skin Cancer: Scoping Review Evidence</title>
		<link>https://molemaxsystems.com/training-primary-care-practitioners-in-dermoscopy-diagnostic-algorithms-enhances-diagnostic-accuracy-and-triage-of-suspected-skin-cancer-scoping-review-evidence/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 10 Mar 2026 01:32:33 +0000</pubDate>
				<category><![CDATA[Evidence & Research]]></category>
		<category><![CDATA[Dermatoscope benefits]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9259</guid>

					<description><![CDATA[<p>Enhancing primary care skin cancer detection through dermoscopy</p>
<p>The post <a href="https://molemaxsystems.com/training-primary-care-practitioners-in-dermoscopy-diagnostic-algorithms-enhances-diagnostic-accuracy-and-triage-of-suspected-skin-cancer-scoping-review-evidence/">Training Primary Care Practitioners In Dermoscopy Diagnostic Algorithms Enhances Diagnostic Accuracy and Triage of Suspected Skin Cancer: Scoping Review Evidence</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a889d7ae332f"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p>Alexandre Ladet, Sandra Lawton, Michael J Boffa</p>
<h3><strong>ABSTRACT</strong></h3>
<p><strong>Introduction</strong>: In many Western countries, access to a dermatologist can be difficult, while the incidence of skin cancer has risen steadily over the past 50 years.</p>
<p><strong>Objective</strong>: We reviewed the published literature to determine whether training primary care practitioners (PCPs) in dermoscopy through brief interventions based on diagnostic algorithms could improve patient care by improving their diagnostic accuracy of suspect lesions.</p>
<p><strong>Methods</strong>: A scoping review of the literature was conducted, focusing on studies published in the period 2003–2023 that assessed the ability of low-experienced PCPs to triage suspicious dermatological lesions using dermoscopic diagnostic algorithms. Regarding outcomes, we focused on quantitative variables relevant to screening practice in general practice, including sensitivity, specificity, referrals to specialists, and unnecessary lesion excisions.</p>
<p><strong>Results</strong>: Of the 926 studies initially identified, 13 were eventually selected: 10 cross-sectional observational studies and three randomized controlled trials. The studies were carried out in North America (N=6), Western Europe (N=4), and Australia (N=3). There was heterogeneity in the training interventions and the criteria used to assess diagnostic accuracy of PCPs after training; however, all studies showed an improvement in this parameter. The preferred algorithms for training PCPs were the 3-point checklist, the 7-point checklist, and the Triage Amalgamated Dermoscopy Algorithm.</p>
<div class="page" data-page-number="1" data-loaded="true">
<div class="textLayer"><strong>Conclusion</strong>: This review demonstrates the value of training PCPs in dermoscopic diagnostic algorithms through short courses to improve triage of suspicious lesions. However, it is still necessary to define a territorial organization, a precise working framework and limits for PCPs who take on this role.</div>
</div>
<div class="textLayer"></div>
<div>To read this article in full <a href="https://dpcj.org/index.php/dpc/article/view/5208/3208" target="_blank" rel="noopener">please click here</a>.</div>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/training-primary-care-practitioners-in-dermoscopy-diagnostic-algorithms-enhances-diagnostic-accuracy-and-triage-of-suspected-skin-cancer-scoping-review-evidence/">Training Primary Care Practitioners In Dermoscopy Diagnostic Algorithms Enhances Diagnostic Accuracy and Triage of Suspected Skin Cancer: Scoping Review Evidence</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dermoscopic Features of Pigmented Bowen Disease in Phototype IV Patients</title>
		<link>https://molemaxsystems.com/dermoscopic-features-of-pigmented-bowen-disease-in-phototype-iv-patients/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 03 Mar 2026 05:19:18 +0000</pubDate>
				<category><![CDATA[Evidence & Research]]></category>
		<category><![CDATA[dematology research]]></category>
		<category><![CDATA[dermoscopy]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9219</guid>

					<description><![CDATA[<p>Understanding dermoscopic features of pigmented Bowen disease</p>
<p>The post <a href="https://molemaxsystems.com/dermoscopic-features-of-pigmented-bowen-disease-in-phototype-iv-patients/">Dermoscopic Features of Pigmented Bowen Disease in Phototype IV Patients</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a889d7ae4ed9"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p>Gabriel Salerni, Horacio Cabo, Emilia N. Cohen-Sabban, Sonia Rodríguez-Saa, Flavia Carolina Pozzobon, Cristian Navarrete-Dechent, Ivonne Arellano-Mendoza, Virginia M. González, Renato Marchiori Bakos, Nicole Orendain, Malynahi Tapia-Juarez, Luis Morales Godinez, Diana Guerrero Hernández, Sofía Andre, Susana Puig</p>
<h3><strong>ABSTRACT</strong></h3>
<p><strong>Introduction</strong>: Research on the dermoscopic features of pigmented Bowen disease (pBD) in individuals with phototype IV skin is limited and consists primarily of case reports or small studies.</p>
<p><strong>Objectives</strong>: We sought to describe the clinical and dermoscopic characteristics of 21 cases of pBD in a skin phototype IV population.</p>
<p><strong>Methods</strong>: We conducted a multicenter retrospective analysis of 21 histopathologically confirmed cases of pBD under the auspices of the Dermoscopy Chapter of the Ibero-Latin American College of Dermatology (CILAD).</p>
<p><strong>Results</strong>: A total of 21 pBD cases in phototype IV patients (57% male, mean age 63.1 years) were analyzed. Lesions were most frequently located on the upper extremities and head and neck area (29% and 24%, respectively) and exhibited brown (90.5%) and pink (90.5%) coloration, with a higher prevalence of gray, black, and blue compared to lighter phototypes. Structureless areas (90.5%) and pigmented dots in a linear arrangement (71.4%) were the most frequent dermoscopic findings. Non-specific dermoscopic findings were observed in 23.8% (N=5) of cases.</p>
<div class="page" data-page-number="2" data-loaded="true">
<div class="textLayer"><strong>Conclusion</strong>: PBD in phototype IV presents with a distinct dermoscopic pattern, including a higher proportion black and blue colors and fewer vascular structures than observed in lighter phototypes. The most prominent dermoscopic findings were structureless areas and pigmented dots, either in a central or peripheral linear arrangement; however, in a quarter of the cases, no specific clue was ob-served. These findings emphasize the need for tailored diagnostic approaches and the importance of biopsy when specific dermoscopic features are absent.</div>
</div>
<div></div>
<div>To read the full article, <a href="https://mail.dpcj.org/index.php/dpc/article/view/5750/3728" target="_blank" rel="noopener">click here</a>.</div>
<div class="page" data-page-number="3" data-loaded="true">
<div class="canvasWrapper"></div>
<div class="textLayer"></div>
</div>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/dermoscopic-features-of-pigmented-bowen-disease-in-phototype-iv-patients/">Dermoscopic Features of Pigmented Bowen Disease in Phototype IV Patients</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Intravascular cutaneous squamous cell carcinoma (cSCC): A rare histopathologic finding with potential prognostic significance</title>
		<link>https://molemaxsystems.com/intravascular-cutaneous-squamous-cell-carcinoma-cscc-a-rare-histopathologic-finding-with-potential-prognostic-significance/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Thu, 22 Jan 2026 03:36:43 +0000</pubDate>
				<category><![CDATA[Evidence & Research]]></category>
		<category><![CDATA[dematology research]]></category>
		<category><![CDATA[skin cancer]]></category>
		<category><![CDATA[Squamous Cell Carcinoma]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9071</guid>

					<description><![CDATA[<p>Understanding vascular invasion in cutaneous squamous carcinoma</p>
<p>The post <a href="https://molemaxsystems.com/intravascular-cutaneous-squamous-cell-carcinoma-cscc-a-rare-histopathologic-finding-with-potential-prognostic-significance/">Intravascular cutaneous squamous cell carcinoma (cSCC): A rare histopathologic finding with potential prognostic significance</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a889d7ae6b4c"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p><span class="corresponding-author" role="listitem"><span class="dropBlock">Alexa S. Podolsky, BS</span></span> ∙ <span role="listitem"><span class="dropBlock">Rachel Manci, MD</span></span> ∙ <span role="listitem"><span class="dropBlock">Samantha S. Sattler, MD</span></span> ∙ <span role="listitem"><span class="dropBlock">Daniel Lozeau, MD</span></span> ∙ <span role="listitem"><span class="dropBlock">Jordan B. Slutsky, MD</span></span></p>
<p>&nbsp;</p>
<h2>Introduction</h2>
<div id="p0010" role="paragraph">Cutaneous squamous cell carcinoma (cSCC) is the second most common cutaneous malignancy, and its incidence continues to increase over time. While cSCC generally portends a favorable prognosis, significant morbidity and mortality are possible in its more advanced stages.<span class="dropBlock reference-citations"><a id="body-ref-sref1-1" class="reference-citations__ctrl" role="doc-biblioref" href="https://www.jaadcasereports.org/article/S2352-5126(25)00434-5/fulltext#" data-xml-rid="bib1" aria-label="Reference 1" aria-expanded="false" data-db-target-for="sref1-1" aria-controls="sref1-1"><sup>1</sup></a></span> The high-risk prognostic factors currently described by the American Joint Committee on Cancer (AJCC) eighth edition and the Brigham and Women’s Hospital (BWH) include tumor diameter greater than 2-cm, depth of invasion beyond the subcutaneous fat, bony invasion, poor-differentiation, and perineural invasion.<span class="dropBlock reference-citations"><a id="body-ref-sref2" class="reference-citations__ctrl" role="doc-biblioref" href="https://www.jaadcasereports.org/article/S2352-5126(25)00434-5/fulltext#" data-xml-rid="bib2" aria-label="Reference 2" aria-expanded="false" data-db-target-for="sref2" aria-controls="sref2"><sup>2</sup></a></span> Intravascular invasion of cSCC is a rare histopathologic finding that is not currently described in either cSCC staging guideline, yet may influence locoregional recurrence and patient prognosis.<span class="dropBlock reference-citations"><a id="body-ref-sref5-1" class="reference-citations__ctrl" role="doc-biblioref" href="https://www.jaadcasereports.org/article/S2352-5126(25)00434-5/fulltext#" data-xml-rid="bib3 bib4 bib5" aria-expanded="false" data-db-target-for="sref5-1" aria-controls="sref5-1"><sup>3-5</sup></a></span> Herein, we present 2 cases of cSCC with intravascular invasion identified during Mohs micrographic surgery (MMS), summarize the prognostic data that are available to date, and provide management recommendations for surgical cases exhibiting this high-risk feature.</div>
<div role="paragraph"></div>
<div role="paragraph">To read the full article please <a href="https://www.jaadcasereports.org/article/S2352-5126(25)00434-5/fulltext" target="_blank" rel="noopener">click here</a>.</div>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/intravascular-cutaneous-squamous-cell-carcinoma-cscc-a-rare-histopathologic-finding-with-potential-prognostic-significance/">Intravascular cutaneous squamous cell carcinoma (cSCC): A rare histopathologic finding with potential prognostic significance</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Dermoscopic Features of Acral Palmoplantar Nevi: Age and Site Correlation in a North African Cohort</title>
		<link>https://molemaxsystems.com/dermoscopic-features-of-acral-palmoplantar-nevi-age-and-site-correlation-in-a-north-african-cohort/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Thu, 08 Jan 2026 00:20:17 +0000</pubDate>
				<category><![CDATA[Evidence & Research]]></category>
		<category><![CDATA[dermatology research]]></category>
		<category><![CDATA[Dermatoscope benefits]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=8963</guid>

					<description><![CDATA[<p>Understanding dermoscopic features of palmoplantar nevi</p>
<p>The post <a href="https://molemaxsystems.com/dermoscopic-features-of-acral-palmoplantar-nevi-age-and-site-correlation-in-a-north-african-cohort/">Dermoscopic Features of Acral Palmoplantar Nevi: Age and Site Correlation in a North African Cohort</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a889d7ae885a"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<div class="wpb_wrapper">
		<p>Meryem Soughi, Oumaima Bouraqqadi, Zakia Douhi, Sara Elloudi, Hanane Baybay, Fatimazahra Mernissi</p>
<h3><strong>ABSTRACT</strong></h3>
<p><strong>Introduction</strong>: Palmoplantar nevi (PPN) are common and sometimes difficult to diagnose because<br />
of their unusual clinical, dermoscopic, and histological features, often mistaken for acral lentiginous<br />
melanoma.</p>
<p><strong>Objective</strong>: This study aimed to investigate the different dermoscopic patterns of palmoplantar nevi<br />
and their correlation with age and location.</p>
<p><strong>Methods</strong>: This was a retrospective-prospective cohort study of a sample of the Moroccan population<br />
collected over 2 years. The diagnosis was based mainly on clinical and dermoscopic evaluation, and a<br />
biopsy performed in a single patient.</p>
<p><strong>Results</strong>: A total of 140 patients with 144 PPNs were included in this study. PPNs were more frequently<br />
located on the palms (64%) than on the soles (36%). The parallel furrow pattern (PFP) was the most<br />
frequent in 44% of patients, followed by the lattice pattern (17,4%), then the homogeneous pattern<br />
(16.7%), the fibrillar pattern (10,4%), the compound pattern (7%), the globular pattern (2 %), the<br />
dotted pattern (2 %), and finally, the atypical pattern (0.7%). We found a correlation between fibrillar<br />
and globular patterns with younger patients (P &lt;0.05) lattice pattern with pressure-free regions such<br />
as the arch and palmar region. In contrast, the fibrillar pattern was associated with heels and PFP with<br />
digital location.</p>
<p><strong>Conclusion</strong>: Recognition of these patterns is crucial for accurate diagnosis and to avoid unnecessary<br />
excisions.</p>
<p>To read the full article please <a href="https://www.dpcj.org/index.php/dpc/article/view/5065" target="_blank" rel="noopener">click here</a>.</p>
	</div>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/dermoscopic-features-of-acral-palmoplantar-nevi-age-and-site-correlation-in-a-north-african-cohort/">Dermoscopic Features of Acral Palmoplantar Nevi: Age and Site Correlation in a North African Cohort</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
